Nesselmann Catharina, Ma Nan, Bieback Karen, Wagner Wolfgang, Ho Anthony, Konttinen Yrjö T, Zhang Hao, Hinescu Mihail E, Steinhoff Gustav
Department of Cardiac Surgery, University of Rostock, Germany.
J Cell Mol Med. 2008 Oct;12(5B):1795-810. doi: 10.1111/j.1582-4934.2008.00457.x. Epub 2008 Aug 5.
Accumulating clinical and experimental evidence indicates that mesenchymal stem cells (MSCs) are promising cell types in the treatment of cardiac dysfunction. They may trigger production of reparative growth factors, replace damaged cells and create an environment that favours endogenous cardiac repair. However, identifying mechanisms which regulate the role of MSCs in cardiac repair is still at work. To achieve the maximal clinical benefits, ex vivo manipulation can further enhance MSC therapeutic potential. This review focuses on the mechanism of MSCs in cardiac repair, with emphasis on ex vivo manipulation.
越来越多的临床和实验证据表明，间充质干细胞（MSCs）是治疗心脏功能障碍的有前景的细胞类型。它们可能触发修复性生长因子的产生，替代受损细胞，并创造有利于内源性心脏修复的环境。然而，确定调节MSCs在心脏修复中作用的机制仍在进行中。为了实现最大的临床益处，体外操作可以进一步增强MSCs的治疗潜力。本综述重点关注MSCs在心脏修复中的机制，尤其强调体外操作。
